Q9D2V5
Gene name |
Aar2 |
Protein name |
Protein AAR2 homolog |
Names |
AAR2 splicing factor homolog |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:68295 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q9D2V5
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q9D2V5-F1 | Predicted | AlphaFoldDB |
22 variants for Q9D2V5
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3392422172 | 41 | V>L | No | EVA | |
| rs3392370819 | 42 | G>E | No | EVA | |
| rs3392431567 | 42 | G>W | No | EVA | |
| rs3388602575 | 47 | G>V | No | EVA | |
| rs13470748 | 59 | Y>* | No | EVA | |
| rs239545125 | 70 | E>D | No | EVA | |
| rs3392422213 | 83 | Q>K | No | EVA | |
| rs3392339571 | 92 | N>T | No | EVA | |
| rs3388590498 | 124 | P>A | No | EVA | |
| rs3388608230 | 130 | L>P | No | EVA | |
| rs232477645 | 166 | F>S | No | EVA | |
| rs264690426 | 186 | R>K | No | EVA | |
| rs3388600122 | 205 | E>* | No | EVA | |
| rs3388602063 | 221 | T>I | No | EVA | |
| rs13470749 | 228 | H>Y | No | EVA | |
| rs3388606132 | 248 | P>R | No | EVA | |
| rs3388596720 | 275 | K>M | No | EVA | |
| rs3388606996 | 317 | I>N | No | EVA | |
| rs3388607195 | 349 | E>K | No | EVA | |
| rs3392473515 | 359 | F>S | No | EVA | |
| rs3388598392 | 360 | R>H | No | EVA | |
| rs3392339599 | 362 | D>N | No | EVA |
No associated diseases with Q9D2V5
1 GO annotations of cellular component
| Name | Definition |
|---|---|
| spliceosomal complex | Any of a series of ribonucleoprotein complexes that contain snRNA(s) and small nuclear ribonucleoproteins (snRNPs), and are formed sequentially during the spliceosomal splicing of one or more substrate RNAs, and which also contain the RNA substrate(s) from the initial target RNAs of splicing, the splicing intermediate RNA(s), to the final RNA products. During cis-splicing, the initial target RNA is a single, contiguous RNA transcript, whether mRNA, snoRNA, etc., and the released products are a spliced RNA and an excised intron, generally as a lariat structure. During trans-splicing, there are two initial substrate RNAs, the spliced leader RNA and a pre-mRNA. |
No GO annotations of molecular function
| Name | Definition |
|---|---|
| No GO annotations for molecular function |
1 GO annotations of biological process
| Name | Definition |
|---|---|
| spliceosomal tri-snRNP complex assembly | The formation of a tri-snRNP complex containing U4 and U6 (or U4atac and U6atac) snRNAs and U5 snRNAs and associated proteins. This includes reannealing of U4 and U6 (or U4atac and U6atac) snRNAs released from previous rounds of splicing to reform the U4/U6 snRNP (or U4atac/U6atac snRNP) as well as the subsequent association of the U5 snRNP with the U4/U6 snRNP (or U4atac/U6atac snRNP) to form a tri-snRNP that is ready to reassemble into another spliceosome complex. |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MSSMQMDPEL | AKQLFFEGAT | VVILNMPKGT | EFGIDYNSWE | VGPKFRGVKM | IPPGIHFLYY |
| 70 | 80 | 90 | 100 | 110 | 120 |
| SSVDKANPRE | VGPRMGFFLS | LKQRGLTVLR | WNAVQEEVDL | SPAPEAEVEA | MRANLPDLDQ |
| 130 | 140 | 150 | 160 | 170 | 180 |
| FLGPYPYATL | KKWISLTNFI | SEATMEKLQP | ESRQICAFSD | VLPVLFMKHT | KDRVGQNLPL |
| 190 | 200 | 210 | 220 | 230 | 240 |
| CGTECRSYQE | GLARLPEMRP | RAGTEIRFSE | LPTQMFPAGA | TPAEITRHSM | DLSYALETVL |
| 250 | 260 | 270 | 280 | 290 | 300 |
| SKQFPGNPQD | VLGELQFAFV | CFLLGNVYEA | FEHWKRLLNL | LCRSESAMGK | YHALYISLIS |
| 310 | 320 | 330 | 340 | 350 | 360 |
| ILYHQLGEIP | ADFFVDIVSQ | DNFLTSTLQV | FFSSACSIAV | EATLRKKAEK | FQAHLTKKFR |
| 370 | 380 | ||||
| WDFTSEPEDC | APVVVELPEG | IETA |